Disulfiram: a novel repurposed drug for cancer therapy

Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram

(2020) Ting Sun et al.   Cell Communication and Signaling

Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties

(2020) Yuya Terashima et al.   Nature Communications

Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway

(2020) Dusana Majera et al.   Cells

Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy

(2020) K. Laxmi Swetha et al.   Pharmacological Reports

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma

(2020) Hirofumi Yoshino et al.   PLoS One

Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model

(2020) Brittney S. Harrington et al.   Cancers

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma

(2019) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma

(2019) Priyanka Shah O’Brien et al.   Journal of Clinical Medicine

Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase

(2019) Zdenek Skrott et al.   ONCOGENE

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells

(2019) Silvia Schmidtova et al.   Cancers

Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel

(2019) Xiao Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly

(2018) Huacheng He et al.   Acta Biomaterialia

Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes

(2018) Saeed Hassani et al.   BIOMEDICINE & PHARMACOTHERAPY

Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer

(2018) Xi Wu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma

(2018) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death

(2018) Young Min Park et al.   PLoS One

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

(2017) Ranjan Bista et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells

(2017) Zhipeng Wang et al.   Nanomedicine-Nanotechnology Biology and Medicine

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

(2017) Zdenek Skrott et al.   NATURE

Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2

(2017) Bing Xu et al.   Cell Death & Disease

Cell cycle specific radiosensitisation by the disulfiram and copper complex

(2017) Mathias Tesson et al.   Oncotarget

Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions

(2017) Yang Jiao et al.   Oncotarget

Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies

(2017) Jay Arora et al.   Oncotarget

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma

(2016) X. Lun et al.   CLINICAL CANCER RESEARCH

A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy

(2016) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models

(2016) Manman Deng et al.   Oncotarget

Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells

(2016) Xinwei Liu et al.   Oncotarget

Targeting copper in cancer therapy: ‘Copper That Cancer’

(2015) Delphine Denoyer et al.   Metallomics

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer

(2015) Jennifer L. Allensworth et al.   Molecular Oncology

A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

(2015) H. Nechushtan et al.   ONCOLOGIST

Concise Review: Bullseye: Targeting Cancer Stem Cells to Improve the Treatment of Gliomas by Repurposing Disulfiram

(2015) Joanna Triscott et al.   STEM CELLS

Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

(2015) Hongbiao Huang et al.   Oncotarget

Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide

(2015) Joanna Triscott et al.   Oncotarget

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

(2015) Richard E. Kast et al.   Oncotarget

Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo

(2015) Peng Liu et al.   Oncotarget

Blocking the formation of radiation–induced breast cancer stem cells

(2015) Yangyang Wang et al.   Oncotarget

Copper Signaling Axis as a Target for Prostate Cancer Therapeutics

(2014) R. Safi et al.   CANCER RESEARCH

On the interaction of copper(ii) with disulfiram

(2014) David J. Lewis et al.   CHEMICAL COMMUNICATIONS

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition

(2014) Jie Zha et al.   Journal of Translational Medicine

Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners

(2014) Tetsuhiro Chiba et al.   PLoS One

Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells

(2013) P Liu et al.   BRITISH JOURNAL OF CANCER

The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells

(2013) C. Rae et al.   JOURNAL OF NUCLEAR MEDICINE

Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC

(2013) R. D. Dinnen et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

(2013) M T Schweizer et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells

(2012) P Liu et al.   BRITISH JOURNAL OF CANCER

Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies

(2012) Concetta Conticello et al.   INTERNATIONAL JOURNAL OF CANCER

Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties

(2011) N C Yip et al.   BRITISH JOURNAL OF CANCER

Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)

(2011) Boris Cvek   DRUG DISCOVERY TODAY